Publication:
Prognostic scores in pulmonary large cell neuroendocrine carcinoma: a retrospective cohort study

dc.contributor.coauthorAkdağ, Goncagül
dc.contributor.coauthorDoğan, Akif
dc.contributor.coauthorYıldırım, Sedat
dc.contributor.coauthorKınıkoğlu, Oğuzcan
dc.contributor.coauthorBatu, Aziz
dc.contributor.coauthorKudu, Emre
dc.contributor.coauthorGeçmen, Gonca Gül
dc.contributor.coauthorIşık, Deniz
dc.contributor.coauthorSever, Özlem Nuray
dc.contributor.coauthorOdabaş, Hatice
dc.contributor.coauthorYıldırım, Mahmut Emre
dc.contributor.coauthorTuran, Nedim
dc.contributor.kuauthorAlan, Özkan
dc.contributor.unitKoç University Hospital
dc.date.accessioned2024-12-29T09:37:38Z
dc.date.issued2024
dc.description.abstractIntroduction: Pulmonary large cell neuroendocrine carcinoma (PLCNEC) is a rare but aggressive subtype of lung cancer with an incidence of approximately 3 %. Identifying effective prognostic indicators is crucial for guiding treatments. This study examined the relationship between inflammatory markers and PLCNEC patient overall survival (OS) and sought to determine their prognostic significance in PLCNEC. Methods: Patients diagnosed with PLCNEC between 2007 and 2022 at the oncology center, were retrospectively included. Patients who underwent surgery were pathologically re-staged postsurgery. Potential prognostic parameters (neutrophil/lymphocyte ratio, platelet/lymphocyte ratio [PLR], panimmune inflammatory value, prognostic nutritional index and modified Glasgow prognostic score [mGPS]) were calculated at that time of diagnosis. Results: Sixty patients were included. The median follow-up was 23 months. Thirty-eight patients initially diagnosed with early or locally advanced. The mGPS was identified as a poor prognostic factor that influenced disease free survival (DFS) fourfold (p = 0.03). All patients' median OS was 45 months. Evaluating factors affecting OS in all patients, statistically significant relationships were observed between OS and the prognostic nutritional index (p = 0.001), neutrophil/ lymphocyte ratio (p = 0.03), platelet/lymphocyte ratio (p = 0.002), and panimmunoinflammatory value (p = 0.005). Upon multivariate analysis, the platelet/lymphocyte ratio was identified as an independent poor prognostic factor for OS, increasing the mortality risk by 5.4 times (p = 0.002). Conclusion: mGPS was significantly linked with prognosis in non-metastatic PLCNEC, with patients with higher mGPS exhibiting poorer long -term DFS. This finding contributes to the evolving understanding of PLCNEC. The multivariable predictive model we employed suggests that PLR is an independent predictor of OS at all stages. A lower PLR was correlated with worse overall survival. Thus, PLR can be a readily accessible and cost-effective prognostic factor in PLCNEC patients.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue3
dc.description.openaccessgold
dc.description.publisherscopeInternational
dc.description.volume10
dc.identifier.doi10.1016/j.heliyon.2024.e25029
dc.identifier.eissn2405-8440
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85183505013
dc.identifier.urihttps://doi.org/10.1016/j.heliyon.2024.e25029
dc.identifier.urihttps://hdl.handle.net/20.500.14288/22431
dc.identifier.wos1176901400001
dc.keywordsPulmonary large cell neuroendocrine carcinoma
dc.keywordsPlatelet/ lymphocyte ratio
dc.keywordsModified glasgow prognostic score
dc.keywordsDisease free survival
dc.keywordsOverall survival
dc.languageen
dc.publisherCell Press
dc.sourceHeliyon
dc.subjectCarcinoid
dc.subjectLung tumor
dc.subjectComputed tomography
dc.titlePrognostic scores in pulmonary large cell neuroendocrine carcinoma: a retrospective cohort study
dc.typeJournal article
dspace.entity.typePublication
local.contributor.kuauthorAlan, Özkan

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR05006.pdf
Size:
893.07 KB
Format:
Adobe Portable Document Format